Anti-DKK3 monoclonal antibody - Stellanova Therapeutics
Alternative Names: Anti-DKK3 antibody; Anti-DKK3 monoclonal antibodyLatest Information Update: 28 Jun 2021
At a glance
- Originator Stellanova Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pancreatic cancer; Triple negative breast cancer
Most Recent Events
- 13 Jun 2021 Pharmacodynamics data from preclinical studies in Pancreatic cancer released by Stellanova Therapeutics
- 03 Jun 2021 Preclinical trials in Pancreatic cancer in USA (Parenteral) before June 2021
- 03 Jun 2021 Preclinical trials in Triple negative Breast cancer in USA (Parenteral) before June 2021